AKT1 and cancer: In this study we evaluated a number of cancer variants that are associated with resistance to endocrine therapy alone or in combination with or without PI3K/AKT/mTOR or CDK4/6 inhibitors, such as PTEN gene copy number loss and ESR1 activating mutations and copy number gain.